EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Development and validation of a duplex droplet digital PCR assay for the simultaneous detection of cytomegalovirus and Epstein-Barr virus in plasma

Zhaoxiang Du, Xingxing Yuan, Sihan Zhou, Lili Zhang, Yifeng Wang, Jie Yi, Manyu Li, Yan Dang, Ning Liu, Xin Liu, Fangfang Dai, Haiqing Sun und 2 weitere

Frontiers in Cellular and Infection Microbiology · 2026

DOI: 10.3389/fcimb.2026.1798127 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Zhaoxiang Du und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Cytomegalovirus, Herpesvirus 4, Human, Cytomegalovirus Infections, Epstein-Barr Virus Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Beijing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Human cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are globally prevalent herpesviruses. While typically self-limiting in immunocompetent individuals, infections can cause severe consequences even in this population. In immunocompromised groups, such as transplant recipients and HIV-infected individuals, viral reactivation or coinfection frequently triggers graft rejection, multi-organ invasion, and malignancies, often exhibiting synergistic pathogenicity. Current serological assays are limited by “window periods” and delayed immune responses, while traditional quantitative PCR (qPCR) relies on standard curves for quantification. Consequently, there is an urgent need for precise, interference-resistant methods. This study aimed to develop and validate a duplex droplet digital PCR (ddPCR) assay for the simultaneous, absolute quantification of CMV and EBV in plasma.

Methods

Based on the TD-1 platform, a single-tube duplex detection system targeting conserved viral regions was optimized to minimize the “rain effect” and maximize signal-to-noise ratios. Leveraging the absolute quantification capability of ddPCR without standard curves, we compared its performance, including dynamic range and limit of detection (LOD), against a homologous qPCR assay. Clinical validation was conducted using 117 plasma samples from suspected cases, utilizing a commercial qPCR kit as the reference standard. Additionally, tolerance to endogenous interfering substances was assessed.

Results

The optimized duplex ddPCR demonstrated high analytical sensitivity, with LODs for CMV and EBV at 7.9 and 6.5 copies/reaction, respectively, which were approximately 6- to 7-fold lower than homologous qPCR (53.4 and 45.6 copies/reaction).No competitive inhibition was observed at low concentrations. In clinical validation, the assay achieved 100% sensitivity and specificity compared to the reference kit, with high quantitative correlation (R 2 = 0.80–0.87). Notably, ddPCR detected four weak positive samples (1 CMV, 3 EBV) missed by homologous qPCR. Furthermore, the method maintained accurate quantification in plasma containing hyperlipidemia or hyperbilirubinemia.

Conclusion

This study successfully established a duplex ddPCR assay characterized by high sensitivity, specificity, and robust interference resistance. By enabling precise absolute quantification, it serves as a powerful complement to existing technologies for the early diagnosis and monitoring of CMV and EBV active infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytomegalovirusHerpesvirus 4, HumanCytomegalovirus InfectionsEpstein-Barr Virus InfectionsReal-Time Polymerase Chain ReactionPlasmaPolymerase Chain ReactionHumansSensitivity and SpecificityDNA, ViralCoinfectionViral LoadLimit of Detection

Stichwörter der Autor:innen

CMVDNAemiaEBVcoinfectionddPCRmolecular assaysqPCR

Substanzen

DNA, Viral

Autor:innen und Institutionen

  • Department of Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
  • Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
  • Division I of In Vitro Diagnostics for Infectious Diseases, Institute for In Vitro Diagnostics Control, National Institutes for Food and Drug Control, Beijing, China.
  • Department of General Surgery, Beijing Youan Hospital, Capital Medical University, Beijing, China.

Förderung

  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Du, Z., Yuan, X., Zhou, S., Zhang, L., Wang, Y., Yi, J., Li, M., Dang, Y., Liu, N., Liu, X., Dai, F., Sun, H., Yu, Y., & Yang, G. (2026). Development and validation of a duplex droplet digital PCR assay for the simultaneous detection of cytomegalovirus and Epstein-Barr virus in plasma. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1798127

Vancouver

Du Z, Yuan X, Zhou S, Zhang L, Wang Y, Yi J, et al. Development and validation of a duplex droplet digital PCR assay for the simultaneous detection of cytomegalovirus and Epstein-Barr virus in plasma. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1798127

BibTeX
@article{Du2026,
  author = {Du, Zhaoxiang and Yuan, Xingxing and Zhou, Sihan and Zhang, Lili and Wang, Yifeng and Yi, Jie and Li, Manyu and Dang, Yan and Liu, Ning and Liu, Xin and Dai, Fangfang and Sun, Haiqing and Yu, Yanhua and Yang, Gengxia},
  title = {Development and validation of a duplex droplet digital PCR assay for the simultaneous detection of cytomegalovirus and Epstein-Barr virus in plasma},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  doi = {10.3389/fcimb.2026.1798127}
}
Kostenlos starten →